US equities |
SPCX $166.84 ▲+4.95% NVDA $236.86 ▲+1.24% MU $1,064.03 ▼-1.01% TSLA $377.62 ▲+1.90% MSFT $526.38 ▲+1.71% SNDK $1,713.68 ▼-0.37% INTC $117.17 ▼-1.81% META $745.17 ▲+2.35%
FinancialContent

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.860 +0.050 (+1.04%)
Delayed Quote Updated: 11:50 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023 ↗
Coya Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Coya Therapeutics ↗
100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha 
Via Talk Markets
News headline image
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in BTIG Fireside Discussion
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases ↗
Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access. 
Via Benzinga
News headline image
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics Announces $26.5 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
News headline image
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon
From Coya Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >